Live federal data · NADAC weekly · Part D CY24

Bromfenac Diclofenac

Bromfenac vs Diclofenac — $700.8M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated 14 Jul 2026

NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Nonsteroidal Anti-inflammatory Drug

Bromfenac

Brand: BROMSITE

First FDA approval: 2013-04-05

Nonsteroidal Anti-inflammatory Drug

Diclofenac

Brand: Cambia

First FDA approval: 1996-03-26

Lowest NADACAcquisition cost floor across all NDCs

$12.97Per unit

$0.066Per unit

Average NADACAcross all dosage forms and strengths

$27.04Up to $115.49

$1.79Up to $12.11

Generic manufacturersActive ANDA holders — FDA Orange Book

710 total ANDAs filed

4164 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$90.4MFull year

$610.4MFull year

Part D claims (CY24)Total fills, all strengths

378K214K beneficiaries

9.4M3.8M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$239Per claim, all NDCs

$65Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

0Zero PA friction

275Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

21Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes7 manufacturers

Yes41 manufacturers